This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Adis Editors. (2012). Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent. Drugs & Therapy Perspectives, 28(12), 20–23. doi:10.1007/BF03262145Adis Editors. (2012). Manage drug-induced parkinsonism through early recognition of the condition and discontinuation of the causative agent. , 28(12), 20–23. doi:10.1007/BF03262145Open DOISearch in Google Scholar
Ahlenius, S., & Ericson, E. (2001). Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats. Journal of Neural Transmission, 108, 415–430.AhleniusS.EricsonE. (2001). Scopolamine does not restore normal conditioned avoidance performance in raclopride-treated rats. , 108, 415–430.Search in Google Scholar
Ali, T., Sisay, M., Tariku, M., Mekuria, A. N., & Desalew, A. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. Plos one, 16(9), e0257129.AliT.SisayM.TarikuM.MekuriaA. N.DesalewA. (2021). Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies. , 16(9), e0257129.Search in Google Scholar
Alty, J., Cosgrove, J., Thorpe, D., & Kempster, P. (2017). How to use pen and paper tasks to aid tremor diagnosis in the clinic. Pract Neurol, 17(6), 456–463. doi:10.1136/practneurol-2017-001719AltyJ.CosgroveJ.ThorpeD.KempsterP. (2017). How to use pen and paper tasks to aid tremor diagnosis in the clinic. , 17(6), 456–463. doi:10.1136/practneurol-2017-001719Open DOISearch in Google Scholar
Alves, G., Forsaa, E., Pedersen, K. F., Gjerstad, M., & Larsen, J. (2008). Epidemiology of Parkinson’s disease. Journal of neurology, 255, 18–32. doi:10.1007/s00415-008-5004-3AlvesG.ForsaaE.PedersenK. F.GjerstadM.LarsenJ. (2008). Epidemiology of Parkinson’s disease. , 255, 18–32. doi:10.1007/s00415-008-5004-3Open DOISearch in Google Scholar
Anand, R., Pandey, S., Garg, R. K., Singh Malhotra, H., Shrivastava, S., Kar, S. K., … Rizvi, I. (2023). Phenomenology, quality of life, and predictors of reversibility in patients with drug-induced movement disorders: a prospective study. CNS Spectr, 28(5), 534–536. doi:10.1017/s1092852922001201AnandR.PandeyS.GargR. K.Singh MalhotraH.ShrivastavaS.KarS. K.RizviI. (2023). Phenomenology, quality of life, and predictors of reversibility in patients with drug-induced movement disorders: a prospective study. , 28(5), 534–536. doi:10.1017/s1092852922001201Open DOISearch in Google Scholar
Baez, M. A., & Avery, J. (2011). Improvement in drug-induced parkinsonism with electro-convulsive therapy. The American Journal of Geriatric Pharmacotherapy, 9(3), 190–193.BaezM. A.AveryJ. (2011). Improvement in drug-induced parkinsonism with electro-convulsive therapy. , 9(3), 190–193.Search in Google Scholar
Bamford, I. J., & Bamford, N. S. (2019). The Striatum’s Role in Executing Rational and Irrational Economic Behaviors. Neuroscientist, 25(5), 475–490. doi:10.1177/1073858418824256BamfordI. J.BamfordN. S. (2019). The Striatum’s Role in Executing Rational and Irrational Economic Behaviors. , 25(5), 475–490. doi:10.1177/1073858418824256Open DOISearch in Google Scholar
Beaulieu, J.-M., & Caron, M. G. (2008). Looking at lithium: molecular moods and complex behaviour. Molecular interventions, 8 (5), 230.BeaulieuJ.-M.CaronM. G. (2008). Looking at lithium: molecular moods and complex behaviour. , 8 (5), 230.Search in Google Scholar
Benítez-Rivero, S., Lama, M. J., Huertas-Fernández, I., de Toledo, P. Á., Cáceres-Redondo, M. T., Martín-Rodríguez, J. F., … Mir, P. (2014). Clinical features and neuropsychological profile in vascular parkinsonism. Journal of the neurological sciences, 345(1-2), 193–197.Benítez-RiveroS.LamaM. J.Huertas-FernándezI.de ToledoP. Á.Cáceres-RedondoM. T.Martín-RodríguezJ. F.MirP. (2014). Clinical features and neuropsychological profile in vascular parkinsonism. , 345(1-2), 193–197.Search in Google Scholar
Blanchet, P. J., & Kivenko, V. (2016). Drug-induced parkinsonism: diagnosis and management. Journal of parkinsonism and restless legs syndrome, 83–91.BlanchetP. J.KivenkoV. (2016). Drug-induced parkinsonism: diagnosis and management. , 83–91.Search in Google Scholar
Bohlega, S., & Al-Foghom, N. B. (2013). Drug-induced Parkinson’s disease. A clinical review. Neurosciences, 18 3, 215–221.BohlegaS.Al-FoghomN. B. (2013). Drug-induced Parkinson’s disease. A clinical review. , 183, 215–221.Search in Google Scholar
Brigo, F., Erro, R., Marangi, A., Bhatia, K., & Tinazzi, M. (2014). Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. Parkinsonism & related disorders, 20(8), 808–814.BrigoF.ErroR.MarangiA.BhatiaK.TinazziM. (2014). Differentiating drug-induced parkinsonism from Parkinson’s disease: an update on non-motor symptoms and investigations. , 20(8), 808–814.Search in Google Scholar
Burkhard, P. R. (2014). Acute and subacute drug-induced movement disorders. Parkinsonism & related disorders, 20, S108–S112.BurkhardP. R. (2014). Acute and subacute drug-induced movement disorders. , 20, S108–S112.Search in Google Scholar
Caroff, S. N., Mu, F., Ayyagari, R., Schilling, T., Abler, V., & Carroll, B. (2018). Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. BMC psychiatry, 18, 1–13.CaroffS. N.MuF.AyyagariR.SchillingT.AblerV.CarrollB. (2018). Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia. , 18, 1–13.Search in Google Scholar
Chen, Y., Lu, T., Jiang, X., & Huang, X. (2021). The effectiveness of specialized nursing interventions for patients with Parkinson disease: A randomized controlled study protocol. Medicine, 100(2), e23972.ChenY.LuT.JiangX.HuangX. (2021). The effectiveness of specialized nursing interventions for patients with Parkinson disease: A randomized controlled study protocol. , 100(2), e23972.Search in Google Scholar
Cunningham Owens, D. G. (2014). Parkinsonism. In D. G. Cunningham Owens (Ed.), A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs (2 ed., pp. 68-133). Cambridge: Cambridge University Press.Cunningham OwensD. G. (2014). Parkinsonism. In Cunningham OwensD. G. (Ed.), (2 ed., pp. 68–133). Cambridge: Cambridge University Press.Search in Google Scholar
Dallapiazza, R., Vloo, P., Fomenko, A., Lee, D., Hamani, C., Munhoz, R., … Kalia, S. (2018). Considerations for Patient and Target Selection in Deep Brain Stimulation Surgery for Parkinson’s Disease. In.DallapiazzaR.VlooP.FomenkoA.LeeD.HamaniC.MunhozR.KaliaS. (2018). . In.Search in Google Scholar
de Germay, S., Montastruc, F., Carvajal, A., Lapeyre-Mestre, M., & Montastruc, J.-L. (2020). Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism & related disorders, 70, 55–59.de GermayS.MontastrucF.CarvajalA.Lapeyre-MestreM.MontastrucJ.-L. (2020). Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. , 70, 55–59.Search in Google Scholar
Diaz-Martinez, A., Benassinni, O., Ontiveros, A., Gonzalez, S., Salin, R., Basquedano, G., & Martinez, R. A. (1998). A randomized, openlabel comparison of venlafaxine and fluoxetine in depressed outpatients. Clinical therapeutics, 20(3), 467–476.Diaz-MartinezA.BenassinniO.OntiverosA.GonzalezS.SalinR.BasquedanoG.MartinezR. A. (1998). A randomized, openlabel comparison of venlafaxine and fluoxetine in depressed outpatients. , 20(3), 467–476.Search in Google Scholar
Draoui, A., El Hiba, O., Aimrane, A., El Khiat, A., & Gamrani, H. (2020). Parkinson’s disease: from bench to bedside. Revue Neurologique, 176(7-8), 543–559.DraouiA.El HibaO.AimraneA.El KhiatA.GamraniH. (2020). Parkinson’s disease: from bench to bedside. , 176(7-8), 543–559.Search in Google Scholar
Druschky, K., Bleich, S., Grohmann, R., Engel, R. R., Toto, S., Neyazi, A., … Stübner, S. (2020). Severe parkinsonism under treatment with antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience, 270, 35–47.DruschkyK.BleichS.GrohmannR.EngelR. R.TotoS.NeyaziA.StübnerS. (2020). Severe parkinsonism under treatment with antipsychotic drugs. , 270, 35–47.Search in Google Scholar
Esper, C. D., & Factor, S. A. (2008). Failure of recognition of drug-induced parkinsonism in the elderly. Movement disorders: official journal of the Movement Disorder Society, 23(3), 401–404.EsperC. D.FactorS. A. (2008). Failure of recognition of drug-induced parkinsonism in the elderly. , 23(3), 401–404.Search in Google Scholar
Faber, R., & Trimble, M. R. (1991). Electro-convulsive therapy in Parkinson’s disease and other movement disorders. Movement disorders: official journal of the Movement Disorder Society, 6(4), 293–303.FaberR.TrimbleM. R. (1991). Electro-convulsive therapy in Parkinson’s disease and other movement disorders. , 6(4), 293–303.Search in Google Scholar
Factor, S. A. (2004). Lithium-induced movement disorders. NEUROLOGICAL DISEASE AND THERAPY, 62, 209–232.FactorS. A. (2004). Lithium-induced movement disorders. , 62, 209–232.Search in Google Scholar
Fountoulakis, K. N., Tohen, M., & Zarate Jr, C. A. (2022). Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. European Neuropsychopharmacology, 54, 100–115.FountoulakisK. N.TohenM.Zarate JrC. A. (2022). Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. , 54, 100–115.Search in Google Scholar
Friedman, J. H. (2014). Challenges in our understanding of neuroleptic induced parkinsonism. Parkinsonism & related disorders, 20(12), 1325–1328.FriedmanJ. H. (2014). Challenges in our understanding of neuroleptic induced parkinsonism. , 20(12), 1325–1328.Search in Google Scholar
Gallagher, S., & Bouchard, L. (2023). Nurse practitioner educational preparation and confidence related to managing antipsychotic medications and associated drug-induced movement disorders. Journal of the American Association of Nurse Practitioners, 10.1097.GallagherS.BouchardL. (2023). Nurse practitioner educational preparation and confidence related to managing antipsychotic medications and associated drug-induced movement disorders. , 10.1097.Search in Google Scholar
Galoppin, M., Berroir, P., Soucy, J. P., Suzuki, Y., Lavigne, G. J., Gagnon, J. F., … Blanchet, P. J. (2020). Chronic neuroleptic-induced parkinsonism examined with positron emission tomography. Movement Disorders, 35 (7), 1189–1198.GaloppinM.BerroirP.SoucyJ. P.SuzukiY.LavigneG. J.GagnonJ. F.BlanchetP. J. (2020). Chronic neuroleptic-induced parkinsonism examined with positron emission tomography. , 35 (7), 1189–1198.Search in Google Scholar
Gershanik, O. S. (1994). Drug-induced parkinsonism in the aged: recognition and prevention. Drugs & aging, 5, 127–132.GershanikO. S. (1994). Drug-induced parkinsonism in the aged: recognition and prevention. , 5, 127–132.Search in Google Scholar
Gordon, J. H., Gorski, R. A., Borison, R. L., & Diamond, B. I. (1980). Postsynaptic efficacy of dopamine: possible suppression by estrogen. Pharmacology Biochemistry and Behavior, 12 (4), 515–518.GordonJ. H.GorskiR. A.BorisonR. L.DiamondB. I. (1980). Postsynaptic efficacy of dopamine: possible suppression by estrogen. , 12 (4), 515–518.Search in Google Scholar
Hirose, G. (2006). Drug induced parkinsonism: a review. Journal of neurology, 253, iii22–iii24.HiroseG. (2006). Drug induced parkinsonism: a review. , 253, iii22–iii24.Search in Google Scholar
Holroyd, S., & Smith, D. (1995). Disabling parkinsonism due to lithium: a case report. Journal of Geriatric Psychiatry and Neurology, 8(2), 118–119.HolroydS.SmithD. (1995). Disabling parkinsonism due to lithium: a case report. , 8(2), 118–119.Search in Google Scholar
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55(3), 181–184. doi:10.1136/jnnp.55.3.181HughesA. J.DanielS. E.KilfordL.LeesA. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. , 55(3), 181–184. doi:10.1136/jnnp.55.3.181Open DOISearch in Google Scholar
Kasten, M., Brüggemann, N., König, I. R., Doerry, K., Steinlechner, S., Wenzel, L., … Lencer, R. (2011). Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology, 214, 729–736.KastenM.BrüggemannN.KönigI. R.DoerryK.SteinlechnerS.WenzelL.LencerR. (2011). Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. , 214, 729–736.Search in Google Scholar
Korczyn, A. D. (2015). Vascular parkinsonism—characteristics, pathogenesis and treatment. Nature Reviews Neurology, 11 (6), 319–326.KorczynA. D. (2015). Vascular parkinsonism—characteristics, pathogenesis and treatment. , 11 (6), 319–326.Search in Google Scholar
Kowal, S. L., Dall, T. M., Chakrabarti, R., Storm, M. V., & Jain, A. (2013). The current and projected economic burden of Parkinson’s disease in the United States. Movement Disorders, 28(3), 311–318.KowalS. L.DallT. M.ChakrabartiR.StormM. V.JainA. (2013). The current and projected economic burden of Parkinson’s disease in the United States. , 28(3), 311–318.Search in Google Scholar
Kumsa, A., Agenagnew, L., Alemu, B., & Girma, S. (2020). Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic. Plos one, 15(7), e0235365.KumsaA.AgenagnewL.AlemuB.GirmaS. (2020). Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic. , 15(7), e0235365.Search in Google Scholar
Lim, T., Ahmed, A., Itin, I., Gostkowski, M., Rudolph, J., Cooper, S., & Fernandez, H. (2013). Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease? International Journal of Neuroscience, 123(3), 170–174.LimT.AhmedA.ItinI.GostkowskiM.RudolphJ.CooperS.FernandezH. (2013). Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson’s disease?, 123(3), 170–174.Search in Google Scholar
López-Sendón, J., Mena, M. A., & G de Yébenes, J. (2013). Drug-induced parkinsonism. Expert opinion on drug safety, 12(4), 487–496.López-SendónJ.MenaM. A.G de YébenesJ. (2013). Drug-induced parkinsonism. , 12(4), 487–496.Search in Google Scholar
López-Sendón, J. L., Mena, M. A., & de Yébenes, J. G. (2012). Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs & aging, 29, 105–118.López-SendónJ. L.MenaM. A.de YébenesJ. G. (2012). Drug-induced parkinsonism in the elderly: incidence, management and prevention. , 29, 105–118.Search in Google Scholar
Martí-Massó, J. F., & Poza, J. J. (1998). Cinnarizine-induced parkinsonism: ten years later. Movement Disorders, 13(3), 453–456.Martí-MassóJ. F.PozaJ. J. (1998). Cinnarizine-induced parkinsonism: ten years later. , 13(3), 453–456.Search in Google Scholar
Mena, M. A., & De Yébenes, J. G. (2006). Drug-induced parkinsonism. Expert opinion on drug safety, 5(6), 759–771. Retrieved from https://www.tandfonline.com/doi/pdf/10.1517/14740338.5.6.759MenaM. A.De YébenesJ. G. (2006). Drug-induced parkinsonism. , 5(6), 759–771. Retrieved from https://www.tandfonline.com/doi/pdf/10.1517/14740338.5.6.759Search in Google Scholar
Moleman, P., Janzen, G., Von Bargen, B. A., Kappers, E. J., Pepplinkhuizen, L., & Schmitz, P. (1986). Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. The American journal of psychiatry, 143(2), 232–234.MolemanP.JanzenG.Von BargenB. A.KappersE. J.PepplinkhuizenL.SchmitzP. (1986). Relationship between age and incidence of parkinsonism in psychiatric patients treated with haloperidol. , 143(2), 232–234.Search in Google Scholar
Mukilan, D., Praveen, D., Chowdary, P. R., & Aanandhi, M. V. (2018). Drug-induced parkinsonism: a review. Drug Invent Today, 10 (2), 212–215.MukilanD.PraveenD.ChowdaryP. R.AanandhiM. V. (2018). Drug-induced parkinsonism: a review. , 10 (2), 212–215.Search in Google Scholar
Pandey, S., Pitakpatapee, Y., Saengphatrachai, W., Chouksey, A., Tripathi, M., & Srivanitchapoom, P. (2023). Drug-Induced Movement Disorders. Paper presented at the Seminars in Neurology.PandeyS.PitakpatapeeY.SaengphatrachaiW.ChoukseyA.TripathiM.SrivanitchapoomP. (2023). . Paper presented at the Seminars in Neurology.Search in Google Scholar
Pitton Rissardo, J., & Caprara, A. L. F. (2023). Neuroimaging Techniques in Differentiating Parkinson’s Disease from Drug-Induced Parkinsonism: A Comprehensive Review. Clinics and Practice, 13(6), 1427–1448.Pitton RissardoJ.CapraraA. L. F. (2023). Neuroimaging Techniques in Differentiating Parkinson’s Disease from Drug-Induced Parkinsonism: A Comprehensive Review. , 13(6), 1427–1448.Search in Google Scholar
Pitton Rissardo, J., Vora, N., Mathew, B., Kashyap, V., Muhammad, S., & Fornari Caprara, A. (2023). Overview of Movement Disorders Secondary to Drugs. Clinics and Practice, 13, 959–976. doi:10.3390/clinpract13040087Pitton RissardoJ.VoraN.MathewB.KashyapV.MuhammadS.Fornari CapraraA. (2023). Overview of Movement Disorders Secondary to Drugs. , 13, 959–976. doi:10.3390/clinpract13040087Open DOISearch in Google Scholar
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., … Deuschl, G. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders, 30(12), 1591–1601. doi:https://doi.org/10.1002/mds.26424PostumaR. B.BergD.SternM.PoeweW.OlanowC. W.OertelW.DeuschlG. (2015). MDS clinical diagnostic criteria for Parkinson’s disease. , 30(12), 1591–1601. doi:https://doi.org/10.1002/mds.26424Search in Google Scholar
Powell, A., Gallur, L., Koopowitz, L., & Hayes, M. W. (2020). Parkinsonism in the psychiatric setting: An update on clinical differentiation and management. BMJ Neurology Open, 2(1).PowellA.GallurL.KoopowitzL.HayesM. W. (2020). Parkinsonism in the psychiatric setting: An update on clinical differentiation and management. , 2(1).Search in Google Scholar
Prell, T., Siebecker, F., Lorrain, M., Tönges, L., Warnecke, T., Klucken, J., … Lorenzl, S. (2020). Specialized staff for the care of people with Parkinson’s disease in Germany: an overview. Journal of Clinical Medicine, 9(8), 2581.PrellT.SiebeckerF.LorrainM.TöngesL.WarneckeT.KluckenJ.LorenzlS. (2020). Specialized staff for the care of people with Parkinson’s disease in Germany: an overview. , 9(8), 2581.Search in Google Scholar
Radder, D. L., de Vries, N. M., Riksen, N. P., Diamond, S. J., Gross, D., Gold, D. R., … Lennaerts, H. H. (2019). Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! Expert review of neurotherapeutics, 19(2), 145–157.RadderD. L.de VriesN. M.RiksenN. P.DiamondS. J.GrossD.GoldD. R.LennaertsH. H. (2019). Multidisciplinary care for people with Parkinson’s disease: the new kids on the block!, 19(2), 145–157.Search in Google Scholar
Reeve, A., Simcox, E., & Turnbull, D. (2014). Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing research reviews, 14, 19–30.ReeveA.SimcoxE.TurnbullD. (2014). Ageing and Parkinson’s disease: why is advancing age the biggest risk factor?, 14, 19–30.Search in Google Scholar
Rissardo, J. P., & Caprara, A. L. F. (2023). Predictors of Drug-Induced Parkinsonism. APIK Journal of Internal Medicine.RissardoJ. P.CapraraA. L. F. (2023). Predictors of Drug-Induced Parkinsonism. .Search in Google Scholar
Rogers, R., Hartigan, S. E., & Sanders, C. E. (2021). Identifying mental disorders in primary care: diagnostic accuracy of the connected mind fast check (CMFC) electronic screen. Journal of clinical psychology in medical settings, 28(4), 882–896.RogersR.HartiganS. E.SandersC. E. (2021). Identifying mental disorders in primary care: diagnostic accuracy of the connected mind fast check (CMFC) electronic screen. , 28(4), 882–896.Search in Google Scholar
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., Mielke, M. M., & Rocca, W. A. (2017). Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. Movement Disorders, 32(2), 227–234.SavicaR.GrossardtB. R.BowerJ. H.AhlskogJ. E.MielkeM. M.RoccaW. A. (2017). Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study. , 32(2), 227–234.Search in Google Scholar
Sethi, K. D. (2003). Differential Diagnosis of Parkinsonism.SethiK. D. (2003). .Search in Google Scholar
Shin, H. W., & Chung, S. J. (2012). Drug-induced parkinsonism. J Clin Neurol, 8(1), 15–21. doi:10.3988/jcn.2012.8.1.15ShinH. W.ChungS. J. (2012). Drug-induced parkinsonism. , 8(1), 15–21. doi:10.3988/jcn.2012.8.1.15Open DOISearch in Google Scholar
Tachibana, K., Matsuura, K., Shindo, A., Matsuyama, H., Ii, Y., Taniguchi, A., & Tomimoto, H. (2020). Symptomatic characteristics of parkinson’s disease induced by neuroleptic drugs, based on a functional neuroimaging diagnosis. Internal Medicine, 59(4), 485–490.TachibanaK.MatsuuraK.ShindoA.MatsuyamaH.IiY.TaniguchiA.TomimotoH. (2020). Symptomatic characteristics of parkinson’s disease induced by neuroleptic drugs, based on a functional neuroimaging diagnosis. , 59(4), 485–490.Search in Google Scholar
Undeberg, M. R., McKeirnan, K. C., & Easley, D. (2022). Respecting the patient’s choice: a case of possible drug-induced parkinsonism. Pharmacy, 10 (1), 10.UndebergM. R.McKeirnanK. C.EasleyD. (2022). Respecting the patient’s choice: a case of possible drug-induced parkinsonism. , 10 (1), 10.Search in Google Scholar
van Munster, M., Stümpel, J., Thieken, F., Ratajczak, F., Rascol, O., Fabbri, M., … Pedrosa, D. J. (2022). The role of Parkinson nurses for personalizing Care in Parkinson’s disease: a systematic review and Meta-analysis. Journal of Parkinson’s Disease, 12 (6), 1807–1831.van MunsterM.StümpelJ.ThiekenF.RatajczakF.RascolO.FabbriM.PedrosaD. J. (2022). The role of Parkinson nurses for personalizing Care in Parkinson’s disease: a systematic review and Meta-analysis. , 12 (6), 1807–1831.Search in Google Scholar
Vasquez Builes, S., Salazar, C., Tieck-Fernández, M., Rojas-Gallego, I., & Díaz Silva, G. (2021). Drug-induced parkinsonism: what should a psychiatrist know? Revista Mexicana de Neurociencia, 22. doi:10.24875/RMN.20000010Vasquez BuilesS.SalazarC.Tieck-FernándezM.Rojas-GallegoI.Díaz SilvaG. (2021). Drug-induced parkinsonism: what should a psychiatrist know?, 22. doi:10.24875/RMN.20000010Open DOISearch in Google Scholar